Ethanamine, 2-(hexylthio)-, hydrochloride | 121028-76-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: Ethanamine, 2-(hexylthio)-, hydrochloride
• 英文别名: 2-hexylsulfanylethanamine;hydrochloride
• CAS: 121028-76-0
• 化学式: C8H20ClNS
• 分子量: 197.77
• InChiKey: RBPXWEAXSBRZBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.68
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS<br/>[FR] LIPIDES BIODÉGRADABLES POUR L'ADMINISTRATION D'AGENTS ACTIFS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2013086354A1

  公开（公告）日：2013-06-13

  The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其中在阳离子脂质的脂质部分（例如，疏水链）中具有一个或多个可生物降解的基团。这些阳离子脂质可以掺入脂质粒子中，用于递送一种活性剂，例如核酸。本发明还涉及包含中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选的甾醇的脂质粒子。脂质粒子还可以进一步包括治疗剂，例如核酸。
• [EN] BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS<br/>[FR] LIPIDES BIODÉGRADABLES RAMIFIÉS À TERMINAISONS ALKYLE ET CYCLOALKYLE DESTINÉS À L'ADMINISTRATION D'AGENTS ACTIFS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2013086322A1

  公开（公告）日：2013-06-13

  The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及具有一个或多个生物可降解基团的阳离子脂质的化学式(I)，所述生物可降解基团位于阳离子脂质的脂质部分（例如，疏水链）中。这些阳离子脂质可以被纳入脂质粒子中，用于传递活性剂，例如核酸。该发明还涉及包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选地固醇的脂质粒子。脂质粒子还可以进一步包括治疗剂，例如核酸。
• Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20150005363A1

  公开（公告）日：2015-01-01

  The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种具有公式（I）的阳离子脂质，其中在脂质部分（例如，疏水链）中具有一个或多个可生物降解的基团。这些阳离子脂质可以被纳入到脂质粒中，以传递活性剂，例如核酸。本发明还涉及包括中性脂质、能够减少聚集的脂质、本发明中的阳离子脂质以及可选的固醇的脂质粒。该脂质粒还可以包括治疗剂，例如核酸。
• BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20130195920A1

  公开（公告）日：2013-08-01

  The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种带有一个或多个可生物降解基团的阳离子脂质，该基团位于脂质部分（如疏水链）内。这些阳离子脂质可以被纳入脂质粒中，以传递活性物质，例如核酸。本发明还涉及包括中性脂质、能够减少聚集的脂质、本发明中的阳离子脂质以及可选的甾醇的脂质粒。该脂质粒还可以进一步包括治疗剂，例如核酸。
• BESIFLOXACIN FOR THE TREATMENT OF RESISTANT ACNE
  申请人：Vyome Therapeutics Limited

  公开号：EP3698793A1

  公开（公告）日：2020-08-26

  The present disclosure relates to formulations comprising besifloxacin for use in the treatment of acne and more specifically resistant acne.

  本公开涉及包含贝西沙星的制剂，用于治疗痤疮，更具体地说是抗药性痤疮。